• Profile
Close

Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings

Acta Neurologica Scandinavica Dec 12, 2017

Tsai JJ, et al. - The researchers examined the clinical efficacy and safety of perampanel as an adjunctive treatment for epileptic seizures. Perampanel tolerability could be improved by slow titration (2 mg every 2-4 weeks). Bedtime administration of perampanel could mitigate somnolence and dizziness. Regarding the potential for behavioral changes and close monitoring, counseling was recommended.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay